Imaavy Demonstrates Durable Hemoglobin Response and Rapid Onset of Effect in Pivotal Phase 2/3 Study in Warm Autoimmune Hemolytic Anemia, an Autoantibody-Driven Disease With No FDA-Approved Therapies
June 12, 2026
June 12, 2026
RARITAN, New Jersey, June 12 -- Johnson and Johnson Innovative Medicine issued the following news release on June 11, 2026:
* * *
IMAAVY(R) (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
* Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglo . . .
* * *
IMAAVY(R) (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
* Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglo . . .